Centiva Capital LP Has $2.70 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Centiva Capital LP boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 50.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,367 shares of the company's stock after purchasing an additional 10,469 shares during the quarter. Centiva Capital LP's holdings in Novo Nordisk A/S were worth $2,698,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Bank of America Corp DE grew its position in shares of Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after purchasing an additional 1,165,955 shares in the last quarter. GQG Partners LLC boosted its stake in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares during the period. Loomis Sayles & Co. L P grew its position in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Folketrygdfondet boosted its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock valued at $765,917,000 after purchasing an additional 40,313 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Novo Nordisk A/S by 1.5% in the 4th quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock worth $715,084,000 after buying an additional 123,681 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on NVO. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $69.08 on Tuesday. The business has a fifty day simple moving average of $71.06 and a 200-day simple moving average of $87.22. The company has a market cap of $310.00 billion, a P/E ratio of 21.00, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is currently 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.